Market Overview:
The global CDK4/6 inhibitors for breast cancer market is expected to grow at a CAGR of XX% during the forecast period from 2018 to 2030. The growth in this market can be attributed to factors such as the increasing incidence of breast cancer, rising awareness about early diagnosis and treatment of breast cancer, and the launch of new CDK4/6 inhibitors. Based on type, the global CDK4/6 inhibitors for breast cancer market is segmented into palbociclib, ribociclib, and abemaciclib. Palbociclib is expected to account for a major share of this market in 2018. Based on application, the global CDK4/6 inhibitors for breast cancer market is segmented into hospital pharmacies, retail pharmacies (clinics), drug stores (drug centers), and other applications. The hospital pharmacies segment accounted for a major share of this market in 2017.
Product Definition:
CDK4/6 inhibitors are a type of drug that blocks the action of CDK4 and CDK6 enzymes. These enzymes are involved in cell division, so by blocking their action, tumors can't grow as quickly. CDK4/6 inhibitors are used to treat certain types of cancer, including breast cancer.
Palbociclib:
Palbociclib is a novel oral drug that is currently under phase II clinical trial for the treatment of metastatic breast cancer. It has shown encouraging results in preclinical models of breast cancer and thus, may be a potential CDK4/6 inhibitor for use in humans.
Ribociclib:
Ribociclib is a type of drug known as cyclin-dependent kinase (CDK) inhibitor. It works by decreasing the amount of cell division in cancer cells. Cell division can lead to the growth of tumors, so by decreasing this process, it helps in reducing tumor size and number.
Application Insights:
The other application segment held the largest share of over 70.0% in 2017. Other applications include cancer treatment centers and research studies. The increasing number of clinical trials with these inhibitors is expected to boost their demand for breast cancer treatment, thereby supporting the overall market growth during the forecast period.
Clinical trials are conducted to prove that a new drug is safe and effective for human use before it is introduced into a formal healthcare setting, which involves rigorous testing on humans under medical supervision. A large number of companies are conducting clinical trials with these inhibitors as they have shown potential in treating various cancers including lung, liver & biliary system, head & neck tumor, gastric tumor and others (ovarian). This factor alone can be considered as one of the key factors contributing towards market growth during the study period.
Regional Analysis:
North America dominated the global CDK4/6 inhibitors market in 2017. This can be attributed to the presence of key players, such as Pfizer Inc.; Merck & Co., Inc.; and Celgene Corporation; in this region. Moreover, these companies are continuously developing newer generation drugs with improved efficacy and reduced adverse effects compared to their existing products. For instance, in May 2018, Pfizer announced that it received U.S. FDA approval for Xofigo™ (idursulfase beta) for the treatment of adult patients with chronic kidney disease progression who have failed on two or more anti-diabetic medications. The company also reported positive results from a phase 2 clinical trial conducted using Xofigo combined with carboplatin/etoposide chemotherapy regimen which is currently under investigation by a larger group at Columbia University Medical Center (CUMC).
Growth Factors:
- Increasing incidence of breast cancer
- Growing awareness about CDK4/6 inhibitors for breast cancer treatment
- Rising demand for targeted therapies
- Technological advancements in the field of oncology
- Availability of reimbursement policies
Scope Of The Report
Report Attributes
Report Details
Report Title
CDK4/6 Inhibitors for Breast Cancer Market Research Report
By Type
Palbociclib, Ribociclib, Abemaciclib
By Application
Hospital, Clinic, Drug Center, Other
By Companies
Pfizer, Beacon Pharmaceuticals, Incepta Pharmaceuticals, Pharmaceuticals, Bluepharma, NANO DARU, Eli Lilly, Novartis
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
195
Number of Tables & Figures
137
Customization Available
Yes, the report can be customized as per your need.
Global CDK4/6 Inhibitors for Breast Cancer Market Report Segments:
The global CDK4/6 Inhibitors for Breast Cancer market is segmented on the basis of:
Types
Palbociclib, Ribociclib, Abemaciclib
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospital, Clinic, Drug Center, Other
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Pfizer
- Beacon Pharmaceuticals
- Incepta Pharmaceuticals
- Pharmaceuticals
- Bluepharma
- NANO DARU
- Eli Lilly
- Novartis
Highlights of The CDK4/6 Inhibitors for Breast Cancer Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Palbociclib
- Ribociclib
- Abemaciclib
- By Application:
- Hospital
- Clinic
- Drug Center
- Other
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the CDK4/6 Inhibitors for Breast Cancer Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
CDK4/6 inhibitors are medications that block the activity of CDK4 and CDK6 proteins. These proteins are important in the growth and progression of many cancers, including breast cancer.
Some of the key players operating in the cdk4/6 inhibitors for breast cancer market are Pfizer, Beacon Pharmaceuticals, Incepta Pharmaceuticals, Pharmaceuticals, Bluepharma, NANO DARU, Eli Lilly, Novartis.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 CDK4/6 Inhibitors for Breast Cancer Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 CDK4/6 Inhibitors for Breast Cancer Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 CDK4/6 Inhibitors for Breast Cancer Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the CDK4/6 Inhibitors for Breast Cancer Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global CDK4/6 Inhibitors for Breast Cancer Market Size & Forecast, 2018-2028
4.5.1 CDK4/6 Inhibitors for Breast Cancer Market Size and Y-o-Y Growth
4.5.2 CDK4/6 Inhibitors for Breast Cancer Market Absolute $ Opportunity
Chapter 5 Global CDK4/6 Inhibitors for Breast Cancer Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 CDK4/6 Inhibitors for Breast Cancer Market Size Forecast by Type
5.2.1 Palbociclib
5.2.2 Ribociclib
5.2.3 Abemaciclib
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global CDK4/6 Inhibitors for Breast Cancer Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 CDK4/6 Inhibitors for Breast Cancer Market Size Forecast by Applications
6.2.1 Hospital
6.2.2 Clinic
6.2.3 Drug Center
6.2.4 Other
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global CDK4/6 Inhibitors for Breast Cancer Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 CDK4/6 Inhibitors for Breast Cancer Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America CDK4/6 Inhibitors for Breast Cancer Analysis and Forecast
9.1 Introduction
9.2 North America CDK4/6 Inhibitors for Breast Cancer Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America CDK4/6 Inhibitors for Breast Cancer Market Size Forecast by Type
9.6.1 Palbociclib
9.6.2 Ribociclib
9.6.3 Abemaciclib
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America CDK4/6 Inhibitors for Breast Cancer Market Size Forecast by Applications
9.10.1 Hospital
9.10.2 Clinic
9.10.3 Drug Center
9.10.4 Other
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe CDK4/6 Inhibitors for Breast Cancer Analysis and Forecast
10.1 Introduction
10.2 Europe CDK4/6 Inhibitors for Breast Cancer Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe CDK4/6 Inhibitors for Breast Cancer Market Size Forecast by Type
10.6.1 Palbociclib
10.6.2 Ribociclib
10.6.3 Abemaciclib
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe CDK4/6 Inhibitors for Breast Cancer Market Size Forecast by Applications
10.10.1 Hospital
10.10.2 Clinic
10.10.3 Drug Center
10.10.4 Other
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific CDK4/6 Inhibitors for Breast Cancer Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific CDK4/6 Inhibitors for Breast Cancer Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific CDK4/6 Inhibitors for Breast Cancer Market Size Forecast by Type
11.6.1 Palbociclib
11.6.2 Ribociclib
11.6.3 Abemaciclib
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific CDK4/6 Inhibitors for Breast Cancer Market Size Forecast by Applications
11.10.1 Hospital
11.10.2 Clinic
11.10.3 Drug Center
11.10.4 Other
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America CDK4/6 Inhibitors for Breast Cancer Analysis and Forecast
12.1 Introduction
12.2 Latin America CDK4/6 Inhibitors for Breast Cancer Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America CDK4/6 Inhibitors for Breast Cancer Market Size Forecast by Type
12.6.1 Palbociclib
12.6.2 Ribociclib
12.6.3 Abemaciclib
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America CDK4/6 Inhibitors for Breast Cancer Market Size Forecast by Applications
12.10.1 Hospital
12.10.2 Clinic
12.10.3 Drug Center
12.10.4 Other
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) CDK4/6 Inhibitors for Breast Cancer Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) CDK4/6 Inhibitors for Breast Cancer Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) CDK4/6 Inhibitors for Breast Cancer Market Size Forecast by Type
13.6.1 Palbociclib
13.6.2 Ribociclib
13.6.3 Abemaciclib
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) CDK4/6 Inhibitors for Breast Cancer Market Size Forecast by Applications
13.10.1 Hospital
13.10.2 Clinic
13.10.3 Drug Center
13.10.4 Other
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 CDK4/6 Inhibitors for Breast Cancer Market: Competitive Dashboard
14.2 Global CDK4/6 Inhibitors for Breast Cancer Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Pfizer
14.3.2 Beacon Pharmaceuticals
14.3.3 Incepta Pharmaceuticals
14.3.4 Pharmaceuticals
14.3.5 Bluepharma
14.3.6 NANO DARU
14.3.7 Eli Lilly
14.3.8 Novartis
